TABLE 2

Potency and efficacy values of monovalent, bivalent, and biparatopic nanobodies in a range of functional assays

Nanobody	Class	[³⁵S]GTPγS Binding				WBNSC		Chemotaxis
		CXCL1		CXCL8		CXCL1		CXCL1
		pIC₅₀	% Inhibition	pIC₅₀	% Inhibition	pIC₅₀	% Inhibition	pIC₅₀	% Inhibition
2B2	Class 1	7.91 ± 0.09^a	77.0 ± 0.3^a	7.86 ± 0.11^a^,^c	80.2 ± 4.2^a^,^b	7.50 ± 0.13^a	71.1 ± 15.5^a	6.81 ± 0.24^a	96.2 ± 4.1^a
127D1	Class 1	8.62 ± 0.07^b	83.2 ± 0.2^a	8.74 ± 0.06^d	88.2 ± 4.5^b^,^c	8.36 ± 0.14^b	91.8 ± 1.0^a^,^b	8.05 ± 0.29^b	92.4 ± 2.4^a
97A9	Class 2	7.31 ± 0.07^c	97.1 ± 1.5^b	7.46 ± 0.08^b	102.5 ± 2.2^d	7.90 ± 0.10^a^,^b	83.1 ± 8.3^a^,^b	7.52 ± 0.31^a^,^b	91.2 ± 11.0^a
163E3	Class 2	7.40 ± 0.13^c	97.2 ± 1.3^b	7.62 ± 0.08^a^,^b	100.4 ± 0.6^c^,^d	8.11 ± 0.17^a^,^b	110.1 ± 9.2^a^,^b	8.23 ± 0.24^b	97.2 ± 3.1^a
163D2	Class 2	7.81 ± 0.01^a	102.2 ± 0.8^b	7.88 ± 0.07^a^,^c	101.9 ± 0.5^d	8.20 ± 0.11^b	94.0 ± 6.2^a^,^b	NT	NT
2B2-9GS-2B2	Class 1	9.51 ± 0.07^d	65.5 ± 2.9^c	9.60 ± 0.06^e	73.7 ± 3.6^a	9.63 ± 0.07^c	99.7 ± 3.5^a^,^b	NT	NT
163E3-35GS-163E3	Class 2	7.99 ± 0.01^a	101.5 ± 1.5^b	8.13 ± 0.06^c	101.0 ± 0.2^c^,^d	8.31 ± 0.11^b	116.0 ± 7.4^b	NT	NT
127D1-35GS-163E3	Biparatopic	8.83 ± 0.09^b	98.8 ± 1.0^b	9.33 ± 0.04^e	101.6 ± 1.4^d	9.96 ± 0.18^c	104.5 ± 3.0^a^,^b	9.85 ± 0.02^c	80.9 ± 11.3^a

NT, not tested; WBNSC, whole blood neutrophil shape change.
Values annotated with the same superscript letter(s) are not statistically significantly different, based on comparison of all nanobody constructs within each assay [and with the same agonist] (P < 0.05; Tukey’s honest significant difference test after one-way analysis of variance).